查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2047077

孕酮市場－全球產業規模、佔有率、趨勢、機會、預測：銷售管道、最終用途、地區和競爭格局分類，2021-2031年

Progesterone Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Sales Channel, By End Use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球孕酮市場預計將成長，從 2025 年的 2.2613 億美元成長到 2031 年的 2.6891 億美元，複合年成長率為 2.93%。

黃體素是一種天然存在的類固醇激素，在調節月經週期、維持懷孕和促進胚胎發育方面發揮至關重要的作用，並已商業性應用於荷爾蒙補充療法（HRT）和輔助生殖技術（ART）。這一市場擴張的主要驅動力是不斷上升的不孕症患病率和越來越多的老年女性尋求更年期症狀的臨床解決方案，此外，人們對荷爾蒙療法安全性的信心增強以及患者接受度的提高也進一步推動了市場成長。例如，更年期協會報告稱，治療方法接受率顯著回升，並預測到2025年，40至60歲女性的荷爾蒙療法使用率將增至13%，這反映了醫療指南的進步。儘管存在這些成長因素，但由於長期使用孕酮可能帶來的健康風險，該市場仍面臨巨大的挑戰。特別是，長期使用類固醇激素會增加乳癌和心血管併發症的風險，由此引發的持續安全擔憂，以及監管力度的加大，繼續引起醫療保健專業人員的焦慮，導致治療處方的持續時間受到限制。

市場概覽
預測期 2027-2031
市場規模：2025年 2.2613億美元
市場規模：2031年 2.6891億美元
複合年成長率：2026-2031年 2.93%
成長最快的細分市場 月經紊亂
最大的市場 亞太地區

市場促進因素

孕酮市場正受到輔助生殖技術 (ART) 和各種不孕症治療日益普及的顯著推動。在體外受精 (IVF) 週期中，孕酮的給藥對於維持黃體期和確保懷孕成功至關重要。隨著全球不孕症治療的普及，對黃體素的依賴性也不斷增強，導致對包括陰道給藥、注射和口服在內的各種劑型的需求不斷成長。輔助生殖技術協會 (SART) 2025 年 4 月的報告也印證了這一趨勢，該報告顯示，孕酮需求量將逐年大幅成長，2023 年會員診所進行的 IVF 週期總數將達到 432,641 個，這與治療性孕酮消耗量的增加直接相關。為了滿足這一特定的臨床需求，生產商正在不斷創新。例如，Besins Healthcare於2025年4月在英國推出了Prometrium 400mg陰道軟膠囊。該產品獲準用於預防早期妊娠出血女性的流產。此外，全球對荷爾蒙補充療法（HRT）的需求不斷成長，是推動市場發展的重要因素。這主要源自於女性人口老化，她們尋求有效緩解更年期症狀並維持長期健康。在這些治療方法中，黃體素對於有子宮的女性至關重要，因為它能預防雌激素引起的子宮內膜增生，從而確保長期處方續開率。這種強勁的需求體現在主要市場處方量的顯著成長。根據英國國家醫療服務體系（NHS）商業服務部門2025年10月發布的報告《荷爾蒙補充療法－英格蘭》，2024/25會計年度HRT處方總量年增11%，達到1,470萬份。如此巨大的市場滲透率凸顯了黃體素在現有醫療保健系統中持續的商業性重要性。

市場挑戰

全球孕酮市場面臨的主要障礙之一是長期荷爾蒙治療帶來的持續健康風險，尤其是乳癌和心血管併發症風險的增加。這些安全隱患對臨床決策產生重大影響，促使醫療專業人員限制處方療程並採取更保守的治療方案。因此，這種醫療謹慎限制了長期維持治療的穩定療效，直接導致全球整體孕酮消費量下降，因為醫生將患者安全置於長期治療方案之上。目前數據顯示荷爾蒙敏感性惡性腫瘤的盛行率進一步凸顯了這些隱患的嚴重性，並加劇了人們對長期使用類固醇的擔憂。美國癌症協會估計，到2025年，美國女性將新增316,950例侵襲性乳癌病例。如此巨大的疾病負擔導致對荷爾蒙補充療法的監管和臨床監督力度加大，迫使醫生嚴格執行較短的治療療程，以最大限度地降低癌症風險。因此，市場成長緩慢，安全治療適應症的範圍仍然受到這些首要安全問題的嚴重限制。

市場趨勢

全球黃體素市場正經歷著向生物等效微粒黃體素的明顯轉變，這從根本上改變了產品格局。患者和臨床醫生越來越傾向於選擇安全性更高、耐受性更好的製劑，以取代合成黃體素。這一趨勢源自於臨床對結構與內源性荷爾蒙相同的分子的需求，旨在降低傳統合成替代藥物以往相關的乳癌和靜脈血栓栓塞症風險。專注於此類製劑的公司業績強勁，其生物等效產品組合的銷售額正快速成長，這為商業性轉變提供了強力的支撐。例如，納斯達克在2025年8月報告稱，TherapeuticsMD的許可收入（主要來自其生物等效荷爾蒙療法）在2025年第二季度飆升至100萬美元，同比成長高達334%。同時，透過遠端保健和數位藥局管道整合孕酮藥物分發正在革新患者的用藥途徑，尤其是在當前區域供應鏈中斷的情況下，這更是一項重要的戰略應對措施。數位平台正逐漸成為關鍵的中介​​機構，提供從諮詢到交付的精簡模式，繞過傳統的實體瓶頸，並透過便利的訂閱服務提高患者的治療依從性。政府旨在降低成本壁壘並確保更年期女性持續護理的舉措進一步推動了這一營運模式的變革，而數位藥房供應商正積極利用這些舉措來維持穩定的庫存水平。例如，英國藥品協會（UK Meds）在2025年1月指出，引入荷爾蒙處方箋（HRT）處方預付憑證將使超過50萬名女性能夠負擔得起HRT，從而直接有助於透過這些現代化的配藥管道穩定滿足市場需求。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球孕酮市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 銷售管道（直接、間接）
    • 依用途分類（荷爾蒙補充療法、不孕症治療、月經失調、月經症候群 (PMS)、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美黃體素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲黃體素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區孕酮市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲孕酮市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲黃體素市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球黃體素市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • NAARI PHARMA Pvt. Ltd
  • La Chandra Pharmalab Pvt. Ltd.
  • BGP Laboratories Private Limited
  • Mankind Pharma Ltd
  • Bhugan Lifescience Pvt Ltd
  • Abcures Biosciences LLP
  • Symbiotec Pharmalab
  • Granth Pharma Pvt Ltd
  • Emote Lifesciences LLP

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 29045

The Global Progesterone Market is projected to experience growth, expanding from USD 226.13 Million in 2025 to USD 268.91 Million by 2031, demonstrating a Compound Annual Growth Rate (CAGR) of 2.93%. Progesterone, a naturally occurring steroid hormone, plays a vital role in regulating the menstrual cycle, sustaining pregnancy, and facilitating embryogenesis, finding commercial application in hormone replacement therapy (HRT) and assisted reproductive technology (ART). This market expansion is primarily driven by the increasing prevalence of infertility and a growing aging female demographic seeking clinical solutions for menopausal symptoms, further bolstered by renewed confidence in the safety profiles of hormonal treatments which has led to higher patient adoption rates. For instance, The Menopause Society reported a significant recovery in therapeutic uptake, with hormone therapy usage among women aged 40 to 60 increasing to 13% in 2025, reflecting evolving medical guidelines. Notwithstanding these growth catalysts, the market faces a considerable obstacle due to the potential health risks associated with long-term progesterone administration. Persistent safety concerns and increased regulatory scrutiny regarding adverse effects, particularly the heightened risk of breast cancer and cardiovascular complications linked to prolonged steroid hormone use, continue to generate apprehension among healthcare providers, thereby limiting the duration of treatment prescriptions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 226.13 Million
Market Size 2031USD 268.91 Million
CAGR 2026-20312.93%
Fastest Growing SegmentMenstrual Disorders
Largest MarketAsia Pacific

Market Driver

The market for progesterone is significantly propelled by the expanding use of Assisted Reproductive Technologies (ART) and various infertility treatments, where progesterone administration is crucial for supporting the luteal phase and achieving successful pregnancies in In Vitro Fertilization (IVF) cycles. This dependency is intensifying as access to fertility services broadens globally, leading to a greater demand for diverse formulations including vaginal, injectable, and oral progesterone. This trend is evidenced by the Society for Assisted Reproductive Technology's April 2025 report, which indicated a substantial year-over-year increase, with the total number of IVF cycles performed at member clinics rising to 432,641 in 2023, directly correlating with higher therapeutic consumption. In response to this specific clinical need, manufacturers are innovating; for example, Besins Healthcare launched Prometrium 400mg soft vaginal capsules in the UK in April 2025, specifically licensed to prevent miscarriage in women experiencing early pregnancy bleeding. Furthermore, the rising global demand for Hormone Replacement Therapy (HRT) acts as a significant market driver, spurred by an aging female population seeking effective management for menopausal symptoms and long-term health maintenance. Within these regimens, progesterone is indispensable for women with an intact uterus, as it prevents estrogen-induced endometrial hyperplasia, thereby ensuring sustained long-term prescription renewal rates. This robust demand is reflected in considerable growth in prescription volumes across key markets; according to the NHS Business Services Authority's October 2025 'Hormone Replacement Therapy - England' report, the total number of HRT items prescribed increased by 11% from the previous year, reaching 14.7 million in 2024/25. Such substantial uptake underscores progesterone's lasting commercial relevance within established healthcare systems.

Market Challenge

A significant impediment to the Global Progesterone Market stems from the enduring health risks associated with prolonged hormone administration, specifically the elevated potential for breast cancer and cardiovascular complications. These safety concerns profoundly impact clinical decision-making, prompting healthcare providers to limit prescription durations and adopt more conservative treatment protocols. Consequently, this medical prudence curtails the potential for consistent revenue from long-term maintenance therapies, directly diminishing the overall global consumption volume of progesterone, as physicians prioritize patient safety over extended therapeutic regimens. The gravity of these concerns is further emphasized by current data illustrating the prevalence of hormone-sensitive malignancies, which sustains apprehension regarding extended steroid usage. The American Cancer Society estimated 316,950 new cases of invasive breast cancer in women in the United States in 2025. This substantial disease burden intensifies regulatory and clinical scrutiny surrounding hormone replacement therapies, compelling physicians to strictly enforce shorter treatment courses to minimize carcinogenic risks and, as a result, the market experiences a constrained growth trajectory, with the window for safe therapeutic application remaining tightly bounded by these overriding safety considerations.

Market Trends

The Global Progesterone Market is experiencing a definitive shift towards bioidentical micronized progesterone, fundamentally transforming the product landscape as both patients and clinicians increasingly favor formulations offering superior safety and tolerability compared to synthetic progestins. This preference is rooted in the clinical desire for molecules that structurally mirror endogenous hormones, thereby aiming to alleviate the perceived risks of breast cancer and venous thromboembolism historically linked with traditional synthetic alternatives. This commercial pivot is substantiated by the robust financial performance of companies specializing in these formulations, which are observing rapid revenue expansion from their bioidentical portfolios; for instance, Nasdaq reported in August 2025 that TherapeuticsMD's license revenue, significantly driven by its bioidentical hormone therapies, surged to $1.0 million in the second quarter of 2025, marking an impressive 334% increase from the prior year. Concurrently, the integration of progesterone distribution through telehealth and digital pharmacy channels is revolutionizing patient access, particularly as a strategic response to persistent regional supply chain disruptions. Digital platforms are emerging as crucial intermediaries, providing streamlined consultation-to-delivery models that circumvent traditional physical bottlenecks and enhance treatment adherence through convenient subscription-based services. This operational evolution is additionally bolstered by government initiatives aimed at reducing cost barriers and ensuring continuous care for menopausal women, which digital providers are actively capitalizing on to maintain consistent stock availability. As an example, UK Meds highlighted in January 2025 that the implementation of the HRT Prescription Prepayment Certificate has successfully facilitated affordable access for over 500,000 women, directly contributing to the stabilization of demand fulfillment via these modern dispensing corridors.

Key Market Players

  • NAARI PHARMA Pvt. Ltd
  • La Chandra Pharmalab Pvt. Ltd.
  • BGP Laboratories Private Limited
  • Mankind Pharma Ltd
  • Bhugan Lifescience Pvt Ltd
  • Abcures Biosciences LLP
  • Symbiotec Pharmalab
  • Granth Pharma Pvt Ltd
  • Emote Lifesciences LLP

Report Scope

In this report, the Global Progesterone Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Progesterone Market, By Sales Channel

  • Direct
  • Indirect

Progesterone Market, By End Use

  • Hormone Replacement Therapy
  • Infertility Treatment
  • Menstrual Disorders
  • Premenstrual Syndrome (PMS)
  • Others

Progesterone Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Progesterone Market.

Available Customizations:

Global Progesterone Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Progesterone Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Sales Channel (Direct, Indirect)
    • 5.2.2. By End Use (Hormone Replacement Therapy, Infertility Treatment, Menstrual Disorders, Premenstrual Syndrome (PMS), Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Progesterone Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Sales Channel
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Progesterone Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Sales Channel
        • 6.3.1.2.2. By End Use
    • 6.3.2. Canada Progesterone Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Sales Channel
        • 6.3.2.2.2. By End Use
    • 6.3.3. Mexico Progesterone Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Sales Channel
        • 6.3.3.2.2. By End Use

7. Europe Progesterone Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Sales Channel
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Progesterone Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Sales Channel
        • 7.3.1.2.2. By End Use
    • 7.3.2. France Progesterone Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Sales Channel
        • 7.3.2.2.2. By End Use
    • 7.3.3. United Kingdom Progesterone Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Sales Channel
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy Progesterone Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Sales Channel
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Progesterone Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Sales Channel
        • 7.3.5.2.2. By End Use

8. Asia Pacific Progesterone Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Sales Channel
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Progesterone Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Sales Channel
        • 8.3.1.2.2. By End Use
    • 8.3.2. India Progesterone Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Sales Channel
        • 8.3.2.2.2. By End Use
    • 8.3.3. Japan Progesterone Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Sales Channel
        • 8.3.3.2.2. By End Use
    • 8.3.4. South Korea Progesterone Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Sales Channel
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia Progesterone Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Sales Channel
        • 8.3.5.2.2. By End Use

9. Middle East & Africa Progesterone Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Sales Channel
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Progesterone Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Sales Channel
        • 9.3.1.2.2. By End Use
    • 9.3.2. UAE Progesterone Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Sales Channel
        • 9.3.2.2.2. By End Use
    • 9.3.3. South Africa Progesterone Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Sales Channel
        • 9.3.3.2.2. By End Use

10. South America Progesterone Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Sales Channel
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Progesterone Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Sales Channel
        • 10.3.1.2.2. By End Use
    • 10.3.2. Colombia Progesterone Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Sales Channel
        • 10.3.2.2.2. By End Use
    • 10.3.3. Argentina Progesterone Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Sales Channel
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Progesterone Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. NAARI PHARMA Pvt. Ltd
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. La Chandra Pharmalab Pvt. Ltd.
  • 15.3. BGP Laboratories Private Limited
  • 15.4. Mankind Pharma Ltd
  • 15.5. Bhugan Lifescience Pvt Ltd
  • 15.6. Abcures Biosciences LLP
  • 15.7. Symbiotec Pharmalab
  • 15.8. Granth Pharma Pvt Ltd
  • 15.9. Emote Lifesciences LLP

16. Strategic Recommendations

17. About Us & Disclaimer